Mustang licenses immunodeficiency gene therapy from St. Jude

Mustang licenses immunodeficiency gene therapy from St. Jude

Source: 
BioCentury
snippet: 

Mustang Bio Inc. (NASDAQ:MBIO) gained exclusive, worldwide rights to develop and commercialize an ex vivo lentiviral gene therapy to treat X-linked severe combined immunodeficiency (SCID) from St. Jude Children's Research Hospital.